These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 31364069)

  • 1. History, Chemistry and Antibacterial Spectrum.
    Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
    Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rediscovering the octapeptins.
    Velkov T; Roberts KD; Li J
    Nat Prod Rep; 2017 Mar; 34(3):295-309. PubMed ID: 28180225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
    Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
    ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins.
    Paterson DL; Bonomo RA
    Adv Exp Med Biol; 2019; 1145():9-13. PubMed ID: 31364068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
    Doymaz MZ; Karaaslan E
    Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
    [No Abstract]   [Full Text] [Related]  

  • 7. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens.
    Roberts KD; Zhu Y; Azad MAK; Han ML; Wang J; Wang L; Yu HH; Horne AS; Pinson JA; Rudd D; Voelcker NH; Patil NA; Zhao J; Jiang X; Lu J; Chen K; Lomovskaya O; Hecker SJ; Thompson PE; Nation RL; Dudley MN; Griffith DC; Velkov T; Li J
    Nat Commun; 2022 Mar; 13(1):1625. PubMed ID: 35338128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviving Polymyxins: Achievements, Lessons and the Road Ahead.
    Li J
    Adv Exp Med Biol; 2019; 1145():1-8. PubMed ID: 31364067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
    Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
    Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
    Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
    Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
    Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colistin, mechanisms and prevalence of resistance.
    Bialvaei AZ; Samadi Kafil H
    Curr Med Res Opin; 2015 Apr; 31(4):707-21. PubMed ID: 25697677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyxins: a new hope in combating Gram-negative superbugs?
    Velkov T; Roberts KD; Thompson PE; Li J
    Future Med Chem; 2016 Jun; 8(10):1017-25. PubMed ID: 27328129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to polymyxins in Gram-negative organisms.
    Jeannot K; Bolard A; Plésiat P
    Int J Antimicrob Agents; 2017 May; 49(5):526-535. PubMed ID: 28163137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
    Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.